Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTaylor, A.-
dc.contributor.authorLee, H.-
dc.contributor.authorBuisman-Pijlman, F.-
dc.identifier.citationFrontiers in Behavioral Neuroscience, 2014; 8(OCT):360-1-360-8-
dc.descriptionMini review article-
dc.description.abstractThe role of endogenous oxytocin as neuromodulator of birth, lactation and social behaviors is well-recognized. Moreover, the use of oxytocin as a facilitator of social and other behaviors is becoming more and more accepted. Many positive effects have been attributed to intranasal oxytocin administration in animals and humans; with current research highlighting encouraging advances in its potential for use in mental health disorders. The new frontier will be investigating the effective use of oxytocin in pediatric populations. Limited animal data is available on this. Large-scale human studies focusing on autism are currently under way, but many other possibilities seem to lie in the future. However, we need to know more about the risks and effects of repeated use on the developing brain and body. This paper will provide an overview of the current understanding of the role of endogenous oxytocin and its related neuropeptide systems in influencing behaviors, in particular attachment, and will review (a) the literature on the use of intranasal oxytocin in young animals, children (age range birth-12 years) and adolescents (age range 13–19 years), (b) the expected benefits and risks based on the current research, and (c) the risks of oxytocin in children with severe psychopathology and early life trauma. The paper will conclude with a clinical perspective on these findings.-
dc.description.statementofresponsibilityAdrienne E. Taylor, Hsu-en Lee and Femke T. A. Buisman-Pijlman-
dc.publisherFrontiers Research Foundation-
dc.rightsCopyright © 2014 Taylor, Lee and Buisman-Pijlman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CCBY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.-
dc.subjectOxytocin; neuropeptide; attachment; pediatric populations; intranasal oxytocin-
dc.titleOxytocin treatment in pediatric populations-
dc.typeJournal article-
dc.identifier.orcidBuisman-Pijlman, F. [0000-0003-2099-6450]-
Appears in Collections:Aurora harvest 2
Pharmacology publications

Files in This Item:
File Description SizeFormat 
hdl_86982.pdfPublished version435.88 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.